- Home
- ANEB vs ACXP Comparison
ANEB vs ACXP Comparison
Compare ANEB & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANEB
- ACXP
- Stock Information
- Founded
- ANEB 2020
- ACXP 2017
- Country
- ANEB United States
- ACXP United States
- Employees
- ANEB N/A
- ACXP N/A
- Industry
- ANEB Biotechnology: Pharmaceutical Preparations
- ACXP Biotechnology: Pharmaceutical Preparations
- Sector
- ANEB Health Care
- ACXP Health Care
- Exchange
- ANEB Nasdaq
- ACXP Nasdaq
- Market Cap
- ANEB 39.0M
- ACXP 8.4M
- IPO Year
- ANEB 2021
- ACXP 2021
- Fundamental
- Price
- ANEB $1.81
- ACXP $0.49
- Analyst Decision
- ANEB Strong Buy
- ACXP Strong Buy
- Analyst Count
- ANEB 2
- ACXP 2
- Target Price
- ANEB $5.50
- ACXP $10.00
- AVG Volume (30 Days)
- ANEB 12.8K
- ACXP 18.5M
- Earning Date
- ANEB 05-13-2025
- ACXP 08-08-2025
- Dividend Yield
- ANEB N/A
- ACXP N/A
- EPS Growth
- ANEB N/A
- ACXP N/A
- EPS
- ANEB N/A
- ACXP N/A
- Revenue
- ANEB N/A
- ACXP N/A
- Revenue This Year
- ANEB N/A
- ACXP N/A
- Revenue Next Year
- ANEB N/A
- ACXP N/A
- P/E Ratio
- ANEB N/A
- ACXP N/A
- Revenue Growth
- ANEB N/A
- ACXP N/A
- 52 Week Low
- ANEB $0.80
- ACXP $0.30
- 52 Week High
- ANEB $3.08
- ACXP $3.33
- Technical
- Relative Strength Index (RSI)
- ANEB 75.06
- ACXP 51.36
- Support Level
- ANEB $1.36
- ACXP $0.43
- Resistance Level
- ANEB $1.60
- ACXP $0.56
- Average True Range (ATR)
- ANEB 0.26
- ACXP 0.10
- MACD
- ANEB 0.03
- ACXP -0.01
- Stochastic Oscillator
- ANEB 49.22
- ACXP 24.89
About ANEB Anebulo Pharmaceuticals Inc.
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company, developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations.
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.